publication . Article . Other literature type . 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Meera Hameed; Ryma Benayed; Jaclyn F. Hechtman; Ahmet Zehir; Meera Prasad; Hongxin Zhang; Laetitia Borsu; Nikolaus Schultz; David Barron; Sarah Phillips; ...
Open Access
  • Published: 08 May 2017 Journal: Nature Medicine, volume 23, pages 703-713 (issn: 1078-8956, eissn: 1546-170X, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
Abstract
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically-defined tumor types, coupled with an expanding portfolio of molecularly-targeted therapies, demands flexible and comprehensive approaches to profile clinically significant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative utilizing a comprehensive assay, MSK-IMPACT, through which we have compiled matched tumor and normal sequence data...
Subjects
free text keywords: General Biochemistry, Genetics and Molecular Biology, General Medicine, Article, Cancer, medicine.disease, medicine, Genomics, Clinical trial, Prospective cohort study, Bioinformatics, Computational biology, Biology, Biomarker (medicine), Gene, Mutation, medicine.disease_cause, Sequence analysis
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
61 references, page 1 of 5

Garraway, LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013; 31: 1806-14 [OpenAIRE] [PubMed]

Varghese, AM, Berger, MF. Advancing clinical oncology through genome biology and technology. Genome Biol. 2014; 15: 427 [OpenAIRE] [PubMed]

Lindeman, NI. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013; 15: 415-53 [PubMed]

Chapman, PB. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-16 [OpenAIRE] [PubMed]

Hyman, DM. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015; 373: 726-36 [OpenAIRE] [PubMed]

Singh, RR. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607-22 [PubMed]

Roychowdhury, S. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011; 3: 111ra121

Frampton, GM. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-31 [OpenAIRE] [PubMed]

Beltran, H. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015; 1: 466-74 [OpenAIRE] [PubMed]

Sholl, LM. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016; 1: e87062 [OpenAIRE] [PubMed]

Cheng, DT. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015; 17: 251-64 [OpenAIRE] [PubMed]

Cerami, E. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-4 [OpenAIRE] [PubMed]

Ciriello, G. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45: 1127-33 [OpenAIRE] [PubMed]

Simen, BB. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch Pathol Lab Med. 2015; 139: 508-17 [PubMed]

Forbes, SA. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2016

61 references, page 1 of 5
Abstract
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically-defined tumor types, coupled with an expanding portfolio of molecularly-targeted therapies, demands flexible and comprehensive approaches to profile clinically significant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative utilizing a comprehensive assay, MSK-IMPACT, through which we have compiled matched tumor and normal sequence data...
Subjects
free text keywords: General Biochemistry, Genetics and Molecular Biology, General Medicine, Article, Cancer, medicine.disease, medicine, Genomics, Clinical trial, Prospective cohort study, Bioinformatics, Computational biology, Biology, Biomarker (medicine), Gene, Mutation, medicine.disease_cause, Sequence analysis
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
61 references, page 1 of 5

Garraway, LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013; 31: 1806-14 [OpenAIRE] [PubMed]

Varghese, AM, Berger, MF. Advancing clinical oncology through genome biology and technology. Genome Biol. 2014; 15: 427 [OpenAIRE] [PubMed]

Lindeman, NI. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013; 15: 415-53 [PubMed]

Chapman, PB. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-16 [OpenAIRE] [PubMed]

Hyman, DM. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015; 373: 726-36 [OpenAIRE] [PubMed]

Singh, RR. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607-22 [PubMed]

Roychowdhury, S. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011; 3: 111ra121

Frampton, GM. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-31 [OpenAIRE] [PubMed]

Beltran, H. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015; 1: 466-74 [OpenAIRE] [PubMed]

Sholl, LM. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016; 1: e87062 [OpenAIRE] [PubMed]

Cheng, DT. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015; 17: 251-64 [OpenAIRE] [PubMed]

Cerami, E. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-4 [OpenAIRE] [PubMed]

Ciriello, G. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45: 1127-33 [OpenAIRE] [PubMed]

Simen, BB. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch Pathol Lab Med. 2015; 139: 508-17 [PubMed]

Forbes, SA. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2016

61 references, page 1 of 5
Any information missing or wrong?Report an Issue